ArticleFrontiers in microbiology2018
Synergistic Activity of Colistin in Combination With Resveratrol Against Colistin-Resistant Gram-Negative Pathogens.
Article in Frontiers in microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 49 citations in OpenAlex.
- Repurposing flufenamic acid as a putative PmrB-directed adjuvant to restore colistin activity inMicrobiology spectrum · 2026Article
- Natural compounds: a promising therapeutic option for managing colistin-resistant bacteria and improving colistin activity.Molecular biology reports · 2026Review
- Penfluridol synergizes with colistin to reverse colistin resistance in Gram-negative bacilli.Scientific reports · 2025Article
- Antibacterial and anti-virulence activity of eco-friendly resveratrol-loaded lipid nanocapsules against methicillin-resistant staphylococcus aureus.Scientific reports · 2025Article
- Advances and mechanisms of traditional Chinese medicine and its active ingredients against antibiotic-resistantJournal of pharmaceutical analysis · 2025Review
- Small molecular adjuvants repurpose antibiotics towards Gram-negative bacterial infections and multispecies bacterial biofilms.Chemical science · 2023Article
- PYED-1 Overcomes Colistin Resistance inPathogens (Basel, Switzerland) · 2023Article
- In vitro synergistic interaction of colistin and other antimicrobials against intrinsic colistin-resistant3 Biotech · 2023Article
- Resveratrol Increases Sensitivity of Clinical Colistin-Resistant Pseudomonas aeruginosa to ColistinMicrobiology spectrum · 2023Article
- Synergistic Activity of Tetrandrine and Colistin againstAntibiotics (Basel, Switzerland) · 2022Article
- Synergistic antibacterial and anti-biofilm activities of resveratrol and polymyxin B against multidrug-resistant Pseudomonas aeruginosa.The Journal of antibiotics · 2022Article
- Antimicrobial Peptides Active in In Vitro Models of Endodontic Bacterial Infections Modulate Inflammation in Human Cardiac Fibroblasts.Pharmaceutics · 2022Article
- Quantitative Pharmacodynamic Characterization of Resistance versus Heteroresistance of Colistin in E. coli Using a Semimechanistic Modeling of Killing Curves.Antimicrobial agents and chemotherapy · 2022Article
- Effects of Traditional Chinese Medicine and its Active Ingredients on Drug-Resistant Bacteria.Frontiers in pharmacology · 2022Review
- Naringenin restores colistin activation against colistin-resistant gram-negative bacteriaFrontiers in microbiology · 2022Article
- Targeting the ATP Synthase inAntibiotics (Basel, Switzerland) · 2021Article
- Will There Ever Be Cure for Chronic, Life-Changing Colistin-ResistantFrontiers in medicine · 2021Article
- Exploring Phenolic Compounds as Quorum Sensing Inhibitors in Foodborne Bacteria.Frontiers in microbiology · 2021Article
- A Comprehensive Study on the Antimicrobial Properties of Resveratrol as an Alternative Therapy.Evidence-based complementary and alternative medicine : eCAM · 2021Review
- Synergistic Activity of Colistin Combined With Auranofin Against Colistin-Resistant Gram-Negative Bacteria.Frontiers in microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.